研究提携_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen,drug development,antibody discovery

Please input keywords

研究提携

オープンイノベーションによる革新的な新薬の研究開発

Biocytogen is actively seeking partnerships for Project Integrum-derived antibody assets and RenMice-based antibody discovery platforms. Biocytogen is committed to advancing novel drug R&D to benefit patients as soon as possible.

Collaboration Models

Antibody Out-licensing

Antibody Co-Development

Antibody Transfer

Technology Platform Out-licensing

Various drug modalities

Established partnerships

50 therapeutic antibody co-development/out-licensing/transfer agreements

42 target-nominated RenMice licensing projects

5 pipeline-based co-development

Disclosed Partners

Worldwide antibody assets or platform partners include Merck KGaA, Janssen, Xencor, ADC Therapeutics, RemeGen and BeiGene.